• Publications
  • Influence
Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability
BackgroundThe recent H1N1 influenza pandemic illustrated the shortcomings of the vaccine manufacturing process. The A/California/07/2009 H1N1 pandemic influenza vaccine or A(H1N1)pdm09 was availableExpand
  • 35
  • 2
Development of a novel recombinant influenza vaccine in insect cells.
  • Clifton E McPherson
  • Medicine, Biology
  • Biologicals : journal of the International…
  • 1 November 2008
Influenza is a highly contagious viral respiratory illness which is best prevented through vaccination. Currently, all US licensed influenza vaccines are produced in embryonated chicken eggs. TheExpand
  • 36
  • 2
A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice
Abstract A recombinant SARS-CoV spike (S) glycoprotein vaccine produced in insect cells in a pre-clinical development stage is described. A truncated version of S glycoprotein, containing onlyExpand
  • 55
  • 1
  • Open Access
Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process.
Multiple different hemagglutinin (HA) protein antigens have been reproducibly manufactured at the 650L scale by Protein Sciences Corporation (PSC) based on an insect cell culture with baculovirusExpand
  • 38
  • 1
  • Open Access
Complete study demonstrating the absence of rhabdovirus in a distinct Sf9 cell line
A putative novel rhabdovirus (SfRV) was previously identified in a Spodoptera frugiperda cell line (Sf9 cells [ATCC CRL-1711 lot 58078522]) by next generation sequencing and extensive bioinformaticExpand
  • 6
  • 1
Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss
BackgroundRecombinant hemagglutinin (rHA) is the active component in Flublok®; a trivalent influenza vaccine produced using the baculovirus expression vector system (BEVS). HA is a membrane boundExpand
  • 10
Improved stability of recombinant hemagglutinin using a formulation containing sodium thioglycolate.
This study was designed to improve the stability of liquid formulations of recombinant influenza hemagglutinin (rHA) and to understand the mechanism of early loss of potency for rHA. The potency ofExpand
  • 6
Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapterExpand
  • 8
  • Open Access
Vaccine Manufacturing--Second Annual visiongain Conference.
The Vaccine Manufacturing--Second Annual visiongain Conference, held in London, included topics covering new technological developments in the field of influenza vaccine research. This conferenceExpand